MS

Peloton’s Robin Arzón shines light on MS at Genentech-backed panel
Medical Marketing and Media
Fri, 08/2/24 - 11:41 am
Genentech
pharma marketing
MS
multiple sclerosis
Sanofi reports findings from Phase II relapsing MS treatment trial
Clinical Trials Arena
Mon, 07/1/24 - 11:00 am
Sanofi
frexalimab
relapsing multiple sclerosis
MS
clinical trials
Forbion-backed biotech Progentos debuts with $65M for MS drug
BioPharma Dive
Mon, 05/20/24 - 05:50 pm
Progentos
Forbion
MS
multiple sclerosis
funding
Royalty Pharma pays startup $525M for stake in Sanofi MS drug
BioPharma Dive
Thu, 05/9/24 - 07:13 pm
Sanofi
Royalty Pharma
MS
ImmuNext
frexalimab
Roche touts near-complete suppression of multiple sclerosis relapse for injectable Ocrevus
Fierce Pharma
Wed, 04/17/24 - 11:33 am
Roche
Ocrevus
MS
multiple sclerosis
AAN
Viatris' launch plans scuttled as FDA rebuffs long-acting MS drug from partner Mapi
Fierce Pharma
Mon, 03/11/24 - 11:32 am
Viatris
FDA
Mapi Pharma
MS
multiple sclerosis
glatiramer acetate depot
Bristol Myers Squibb reports data from Phase III multiple sclerosis trial
Clinical Trials Arena
Fri, 03/1/24 - 11:39 am
Bristol Myers Squibb
clinical trials
Zeposia
MS
multiple sclerosis
Sanofi shares positive results from trial of frexalimab for MS
Clinical Trials Arena
Fri, 02/16/24 - 11:43 am
Sanofi
clinical trials
MS
multiple sclerosis
frexalimab
Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda
Fierce Pharma
Thu, 01/11/24 - 08:45 pm
Biogen
Fampyra
MS
multiple sclerosis
Acorda Therapeutics
5 FDA Decisions to Watch in Q1
BioSpace
Tue, 01/2/24 - 11:24 am
FDA
Iovance Biotherapeutics
melanoma
lifileucel
Minerva Neurosciences
schizophrenia
roluperidone
Viatris
Mapi Pharma
MS
multiple sclerosis
GA Depot
Madrigal Pharmaceuticals
NASH
resmetirom
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
beta thalassemia
Europe revokes marketing authorization for generic versions of Biogen's MS drug
Reuters
Tue, 12/19/23 - 10:08 am
Biogen
Tecfidera
MS
multiple sclerosis
Europe
generics
Merck KGaA’s BTK Inhibitor Fails Phase III Multiple Sclerosis Studies
BioSpace
Wed, 12/6/23 - 10:44 am
Merck KGaA
evobrutinib
clinical trials
relapsing multiple sclerosis
MS
Genentech's MS drug on partial hold in US after liver enzyme elevations in 2 patients
Fierce Biotech
Mon, 12/4/23 - 06:14 pm
Genentech
Roche
MS
multiple sclerosis
fenebrutinib
clinical trials
Merck KGaA, with hold still clouding prospects, guides MS drug past durability test ahead of phase 3 data
Fierce Biotech
Wed, 10/11/23 - 10:20 am
Merck KGaA
evobrutinib
MS
multiple sclerosis
clinical trials
Roche preps for filings after subcutaneous Ocrevus matches up to IV formulation in phase 3 study
Fierce Pharma
Wed, 10/11/23 - 10:07 am
Roche
Ocrevus
MS
multiple sclerosis
clinical trials
A Breakthrough in Interferon-based Therapies for Multiple Sclerosis
BioSpace
Wed, 09/27/23 - 10:08 am
Heligenics
MS
multiple sclerosis
beta interferon
genomics
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
BioSpace
Fri, 08/25/23 - 09:53 am
Biogen
Sandoz
FDA
biosimilars
MS
multiple sclerosis
Tysabri
Teva's trial in high-stakes kickbacks case delayed as company pursues rare pretrial appeal
Fierce Pharma
Wed, 08/16/23 - 11:11 pm
Teva Pharmaceutical
kickbacks
Copaxone
MS
multiple sclerosis
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Mon, 08/7/23 - 10:32 am
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
TG shares tumble following licensing deal for MS drug
BioPharma Dive
Tue, 08/1/23 - 10:24 pm
TG Therapeutics
MS
multiple sclerosis
Briumvi

Pages